Hypokalemia: A Complete Clinical Approach

Pathophysiology: Three Core Mechanisms

1. Low Intake

• Poor oral intake (alcoholism, starvation, postoperative K+-poor IV fluids)
• When dietary K+ is zero, obligatory renal losses still occur (~5-10 mEq/day minimum)
• Average daily K+ intake: ~75 mEq/day (men), ~55 mEq/day (women); ~85-90% is absorbed in the GI tract

2. Transcellular Shift (Redistribution)

3. Excess Loss

Causes by Category

• Diuretics (loop and thiazides - most common cause; affects up to 50% of patients)
• Mineralocorticoid excess: primary hyperaldosteronism, secondary hyperaldosteronism, Cushing's, ectopic ACTH, apparent mineralocorticoid excess, Liddle syndrome
• Renal tubular acidosis (type 1 and type 2)
• Bartter syndrome, Gitelman syndrome (hereditary tubular disorders)
• Hypomagnesemia (reduces inhibitory effect on luminal K+ channels)
• Osmotic diuresis (DKA, uncontrolled DM)
• Nonreabsorbable anions in tubule (bicarbonate in vomiting, beta-hydroxybutyrate in DKA, penicillin antibiotics)
• Nephrotoxins: amphotericin B, aminoglycosides, cisplatin, ifosfamide

• GI losses: diarrhea (K+-rich stool), vomiting/NG suction (volume depletion → secondary hyperaldosteronism)
• Excessive perspiration
• Dialysis, plasmapheresis

Diagnostic Algorithm

Step 1: Rule out pseudohypokalemia

• Check if WBC is markedly elevated; if so, process sample on ice immediately

Step 2: Is there transcellular redistribution?

• History: insulin given recently, beta-agonist use, periodic paralysis, alkalosis
• If yes, treat the underlying cause; do not aggressively supplement (risk of rebound hyperkalemia)

Step 3: True K+ deficit - check 24-hour urine K+ (or spot urine K+/Cr ratio)

Step 4: If renal loss - check acid-base status

• Renal tubular acidosis type 1 (distal) or type 2 (proximal)
• DKA (osmotic diuresis + beta-hydroxybutyrate as non-reabsorbable anion)

Step 5: If mineralocorticoid excess - check blood pressure

Clinical Manifestations

• Skeletal muscle weakness (proximal > distal), myalgia
• Flaccid paralysis (respiratory failure if severe)
• Rhabdomyolysis (reduced skeletal muscle blood flow from impaired nitric oxide release)
• Paralytic ileus

• ECG changes: flattening/inversion of T waves, prominent U waves, ST depression, widened QRS (severe)
• Ventricular tachycardia, ventricular fibrillation, sudden cardiac death
• Particularly dangerous in patients on digoxin (digoxin toxicity potentiated by hypokalemia) and those with coronary artery disease

• Impaired insulin secretion + insulin resistance → worsened glycemic control
• Metabolic alkalosis (K+ exits cells in exchange for H+)

• Nephrogenic diabetes insipidus (polyuria, polydipsia)
• Hypokalemic nephropathy/tubulointerstitial fibrosis (outer medulla most affected)
• Increased blood pressure (K+ depletion promotes Na+ retention via NCC and ENaC upregulation)

Treatment

General Principles

• Oral route is preferred whenever possible
• IV is reserved for: unable to take oral, symptomatic hypokalemia (arrhythmia, paralysis), K+ < 2.5-3.0 mEq/L
• Always check and replete magnesium first/simultaneously - hypomagnesemia causes ongoing urinary K+ wasting and will prevent K+ correction
• Avoid glucose-containing IV fluids (insulin spike will further lower K+)

Oral Replacement

• KCl is the preferred salt in most situations - also corrects coexisting metabolic alkalosis
• Potassium citrate - preferred in metabolic acidosis (e.g., RTA)
• Potassium phosphate - when concurrent phosphate deficiency (refeeding, DKA)
• Avoid potassium gluconate - a non-reabsorbable anion that may be ineffective
• Dose: 40-100 mmol/day depending on deficit

IV Replacement

• Usual concentration: 20-40 mmol K+ in 1 L NS
• Max peripheral rate: 10-20 mmol/hour
• If K+ < 3.0 mmol/L or rate > 10 mmol/hour: continuous cardiac monitoring required
• Central line needed for higher concentrations (extravasation of KCl causes tissue necrosis)
• Do NOT use dextrose-containing solutions for K+ replacement

Ongoing/Maintenance

• Treat the underlying cause (stop offending drugs if possible)
• For diuretic-induced hypokalemia requiring continued diuretics: add potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene)
• For primary hyperaldosteronism: mineralocorticoid receptor antagonist or surgical resection
• Target K+ ≥ 4.0 mEq/L especially in high-risk patients (cardiac disease, digoxin use)

Special Situations

• Prerenal azotemia + hyperglycemia or metabolic alkalosis: give K+ prophylactically with saline resuscitation - volume expansion alone can cause life-threatening kaliuresis
• DKA: K+ often appears normal or high initially but is severely depleted; begin K+ replacement when serum K+ < 5.0 mEq/L (and hold insulin until K+ ≥ 3.5 mEq/L)
• Refeeding syndrome/alcoholism: often have concurrent hypophosphatemia, hypomagnesemia - all three must be repleted
• Cancer patients: hypokalemia common from multiple overlapping causes - check for cisplatin nephrotoxicity, ectopic ACTH, lysozymuria (AML subtypes M4/M5)

Key Pearls

1. Always check Mg2+ - refractory hypokalemia is usually due to uncorrected hypomagnesemia
2. Vomiting causes hypokalemia via secondary hyperaldosteronism (volume depletion), not primarily from gastric K+ loss (gastric K+ content is low ~10 mEq/L); the urine Cl- will be low (<10 mmol/day)
3. Diarrhea causes hypokalemia via direct K+ loss in stool (stool K+ content is high); urine K+ will be appropriately low
4. Bartter vs Gitelman: Bartter (furosemide-like: hypercalciuria, normal Mg) vs Gitelman (thiazide-like: hypocalciuria, hypomagnesemia)
5. RTA type 4 (hypoaldosteronism) causes hyperkalemia, not hypokalemia - unlike types 1 and 2
6. For every 0.3 mEq/L fall in serum K+ below 3.5, approximately 100 mEq of total body K+ deficit exists (rough guide, varies with acid-base status)
7. Avoid administering K+ too fast - potassium traverses the extracellular space before entering intracellular stores, making rapid IV infusion dangerous